Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 24, 2025

Granules India's Q3 profit falls on weak drug pricing in Europe

(Reuters) - Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market.

Consolidated profit fell to 1.18 billion rupees ($13.7 million) for the quarter ended Dec.31, from 1.26 billion rupees a year earlier.

Granules, which generates about two-thirds of its revenue from North America and 10% from Europe, posted a 1.5% fall in its revenue from operations.

Revenue from North America rose 16% year-on-year, while that from Europe declined 55%.

For further earnings highlights, click.

KEY CONTEXT

Granules, which holds a 30% share of the global paracetamol market, supplies the drug as an active pharmaceutical ingredient (API) and as a finished dosage form - ready for consumption - in Europe, Canada, and South Africa. APIs are the active and key components in a drug that produce the intended therapeutic effects.

Indian API makers have been grappling with weak pricing in key European and North American markets due to tough competition, even as global drugmakers turn to India to limit their reliance on Chinese contractors.

PEER COMPARISON

Estimates (next Analysts' sentiment

12 months)

RIC PE EV/EBIT Revenue Profit Mean # of Stock to Div

DA growth growth rating* analysts price yield

(%) (%) target** (%)

Granules India 23.85 13.60 11.75 27.90 Strong 4 0.89 0.25

Buy

Alivus Life 24.51 16.21 13.87 16.73 Strong 5 1.04 1.96

Sciences Buy

Laurus Labs 60.36 24.90 15.45 88.32 Hold 11 1.27 0.14

Divi's 61.78 43.44 16.77 28.45 Hold 21 1.10 0.52

Laboratories

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

OCTOBER TO DECEMBER STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 86.1660 Indian rupees

(Reporting by Kashish Tandon in Bengaluru; Editing by Eileen Soreng)

Recommended for you

  • Brookfield to invest 20 billion euros in AI projects in France, Tribune reports

  • Ukraine's military says it shot down 70 out of 151 drones launched by Russia overnight

  • China to roll back clean power subsidies after boom